Larimar Stock Slides 15% Despite FDA Backing Rolling Submission For Rare Disease Drug - Larimar Therapeut

Larimar Therapeutics Inc (LRMR) submits first module of Biologics License Application for investigational treatment for Friedreich's ataxia, with FDA support and positive long-term data showing durable safety profile and clinical improvements compared to natural history data.

Raccontata dabenzinga.com